Pharma-Bio Serv (PBSV) Common Equity (2010 - 2026)

Pharma-Bio Serv's Common Equity history runs 17 years deep, the most recent figure standing at $11.0 million for Q2 2026.

• Quarterly Common Equity fell 8.97% year-over-year to $11.0 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $11.0 million (down 8.97% YoY) and the FY2025 annual result came in at $12.5 million, down 8.91% from the prior year.
• Common Equity was $11.0 million for Q2 2026 at Pharma-Bio Serv, up from $10.2 million in the prior quarter.
• Across five years, Common Equity topped out at $17.4 million in Q1 2022 and bottomed at $10.2 million in Q1 2026.
• A 5-year average of $14.2 million and a median of $14.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity tumbled 32.26% — and 2023, when it climbed 0.23%.
• Pharma-Bio Serv's Common Equity stood at $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then slipped by 14.95% to $13.7 million in 2024, then fell by 8.91% to $12.5 million in 2025, then declined by 11.67% to $11.0 million in 2026.
• Business Quant data shows PBSV's Common Equity at $11.0 million in Q2 2026, $10.2 million in Q1 2026, and $12.5 million in Q4 2025.